Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06068543
PHASE2

Reducing Frailty for Older Cancer Survivors Using Supplements II

Sponsor: University of Rochester

View on ClinicalTrials.gov

Summary

This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.

Official title: A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

118

Start Date

2024-10-25

Completion Date

2030-12-31

Last Updated

2026-03-06

Healthy Volunteers

No

Interventions

DRUG

Epigallocatechin-3-Gallate (EGCG)

800mg Epigallocatechin-3-Gallate (EGCG)

DRUG

Microcrystalline cellulose (MCC)

800mg microcrystalline cellulose (MCC)

DIETARY_SUPPLEMENT

Ascorbic Acid (Vitamin C)

250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks

Locations (1)

University of Rochester

Rochester, New York, United States